Bath scientists stabilise vaccine proteins with ensilication
A new system for delivering vaccines to children in low-income nations has taken a vital step forward, thanks to groundbreaking work at the University of Bath
Vaccines are notoriously difficult to transport to remote or dangerous places, as they spoil when not refrigerated. Formulations are safe between 2°C and 8°C, but at other temperatures the proteins start to unravel, making the vaccines ineffective. As a result, millions of children around the world miss out on life-saving inoculations.
However, scientists have now found a way to prevent warmed-up vaccines from degrading. By encasing protein molecules in a silica shell, the structure remains intact even when heated to 100°C, or stored at room temperature for up to three years.
The technique for tailor-fitting a vaccine with a silica coat – known as ensilication – was developed by a Bath team in collaboration with the University of Newcastle. This pioneering technology was seen to work in the lab two years ago, and now it has demonstrated its effectiveness in the real world too.
The researchers explain the significance of their findings
In their latest study, published in the journal Scientific Reports, the researchers sent both ensilicated and regular samples of the tetanus vaccine from Bath to Newcastle by ordinary post (a journey time of over 300 miles, which by post takes a day or two). When doses of the ensilicated vaccine were subsequently injected into mice, an immune response was triggered, showing the vaccine to be active. No immune response was detected in mice injected with unprotected doses of the vaccine, indicating the medicine had been damaged in transit.
Dr Asel Sartbaeva, who led the project from the University of Bath’s Department of Chemistry, said: “This is really exciting data because it shows us that ensilication preserves not just the structure of the vaccine proteins but also the function – the immunogenicity.”
“This project has focused on tetanus, which is part of the DTP (diphtheria, tetanus and pertussis) vaccine given to young children in three doses. Next, we will be working on developing a thermally-stable vaccine for diphtheria, and then pertussis. Eventually we want to create a silica cage for the whole DTP trivalent vaccine, so that every child in the world can be given DTP without having to rely on cold chain distribution.”
Cold chain distribution requires a vaccine to be refrigerated from the moment of manufacturing to the endpoint destination.
Silica is an inorganic, non-toxic material, and Dr Sartbaeva estimates that ensilicated vaccines could be used for humans within five to 15 years. She hopes the technology to silica-wrap proteins will eventually be adopted to store and transport all childhood vaccines, as well as other protein-based products, such as antibodies and enzymes.
“Ultimately, we want to make important medicines stable so they can be more widely available,” she said. “The aim is to eradicate vaccine-preventable diseases in low income countries by using thermally stable vaccines and cutting out dependence on cold chain.”
Currently, up to 50% of vaccine doses are discarded before use due to exposure to suboptimal temperatures. According to the World Health Organisation (WHO), 19.4 million infants did not receive routine life-saving vaccinations in 2018.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Vaccines
- Negativity About Vaccination On Twitter Increases After COVID-19 Vaccines Become Available
Following the availability of COVID-19 vaccines, there was a noticeable surge in negativity surrounding vaccines on Twitter. Researchers at the ESCMID Global Congress (formerly ECCMID) in Barcelona, ...
- WHO picks JN.1 variant for next set of COVID vaccines
The World Health Organization has recommended updating COVID-19 vaccine formulations to reflect the dominant SARS-CoV-2 variant, JN.1. Read more here.
- Vaccines saved at least 154 million lives in 50 years—WHO
Global immunization efforts have saved at least 154 million lives in the past 50 years, the World Health Organization (WHO) said Wednesday, adding that most of those to benefit were infants. That is ...
- Longhorn Vaccines and Diagnostics Presents New Data on its Best-In-Class Infectious Disease Vaccine and Antibody Portfolio at ECCMID 2024
Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive data from three key studies of its ...
- DRC is seeing its worst mpox outbreak — but has no vaccines or treatments yet. Why?
With nearly 5,000 cases reported so far this year — and concerns about a new strain — the Democratic Republic of Congo is considering the declaration of a public health emergency.
Go deeper with Google Headlines on:
Vaccines
[google_news title=”” keyword=”vaccines” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Thermally-stable vaccine
- Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africa
Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africa: Princeton, New Jersey Saturday, April 27, 2024, 11:00 Hrs [IST] Soligenix, Inc, a ...
- Soligenix extends patent protection for its filovirus vaccine platform to the UK and South Africa
Soligenix announced it has received notice of intent to grant additional patents based on its patent application in the UK and South Africa.
- Vaccines News
Mar. 12, 2024 — Researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to ... Optimizing Boosters ...
- VBIV VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV ...
- Thermally Stable and Flame Retardant Polymer Nanocomposites
Special attention is paid to practical examples, walking the reader through the numerous commercial applications of thermally stable and flame retardant nanocomposites. With a strong focus on placing ...
Go deeper with Google Headlines on:
Thermally-stable vaccine
[google_news title=”” keyword=”thermally-stable vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]